Added to YB: 2025-09-11
Pitch date: 2025-07-16
ABEO [bullish]
Abeona Therapeutics Inc.
+2.24%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States.
Market Cap
$364.8M
Pitch Price
$6.26
Price Target
N/A
Dividend
N/A
EV/EBITDA
-2.48
P/E
7.00
EV/Sales
15.11
Sector
Biotechnology
Category
growth
Show full summary:
Riverwater Partners Micro Opportunities Strategy New Position: Abeona Therapeutics Inc.
ABEO (new position): First-mover in curative gene therapy for rare skin diseases. FDA-approved Zevaskyn shows 81% efficacy (≥50% wound healing) vs chronic rival Vyjuvek. $3.1M price/patient, high 80s% gross margins, ~150 U.S. patients addressable. Vertical manufacturing reduces risks.
Read full article (1 min)